Search 

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn’s products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at www.helsinn.com.

Hermo Pharma Ltd is a clinical stage biopharmaceutical company discovering and developing cutting-edge therapeutic products and approaches for currently untreatable medical needs in the field of neurology. Company’s headquarter is located in Helsinki, Finland. The company outsources the majority of operational R&D tasks to external vendors, while controlling the key technology assets and strategic partnerships.

The company’s R&D programs are based on scientifically innovative concepts. These concepts are being developed by the company through preclinical and clinical Phase II proof-of-principal trials and after that Hermo Pharma will seek partnerships to support Phase III trials and market its products worldwide. Currently Hermo Pharma’s product development focus is on novel disease-modifying treatments for amblyopia in adults and Parkinson’s disease.

Amblyopia in Adults. The project is currently in Phase IIa clinical trials and the results seems very promising. Company is expecting to out-license this product latest in early 2014.

Parkinson´s Disease. Company is currently finalizing the pre-clinical proof-of-concepts studies with the support of M.J.Fox Foundation financing. The therapy is based on the neuroprotective and restorative effects provided by the CDNF protein. The clinical strategy includes of testing of intracrainial delivery platform to treat the patients. The current data looks very promising and the company is expecting to proceed into the IND enabling Toxicology phase during year 2013.